# China NMPA Drug Inspection - Guangxi Nanning Dezhi Pharmaceutical Co., Ltd. - safflower

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/guangxi-nanning-dezhi-pharmaceutical-co-ltd/5949d797-70f1-4b9f-b1bd-789546b61026/
Source feed: China

> China NMPA drug inspection for Guangxi Nanning Dezhi Pharmaceutical Co., Ltd. published January 12, 2017. Drug: safflower. 

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement No. 5 of 2017 from the State Administration for Market Regulation on the Results of Special Sampling Inspections of Chinese Medicinal Herbs and Prepared Slices
- Company Name: Guangxi Nanning Dezhi Pharmaceutical Co., Ltd.
- Publication Date: 2017-01-12
- Drug Name: safflower
- Inspection Finding: Acid Red 73, Carmine, Tartrazine, Orange II, or Sunset Yellow were detected, indicating staining issues. Additionally, some batches of products did not meet the standard requirements for appearance, identification, impurities, or content determination.
- Action Taken: We have taken timely and lawful measures to control the products, including sealing and seizing, suspending production and sales, and requiring companies to voluntarily recall their products. We have also filed cases against the relevant companies and units for investigation and punishment.

Company: https://www.globalkeysolutions.net/companies/guangxi-nanning-dezhi-pharmaceutical-co-ltd/c58c2a1e-924c-4ce3-843b-c8bc11561a40/